Several studies investigating the potential of BMPs indicated that other members of the BMP family, different than the currently used BMP-2 and BMP-7, might provide attractive alternatives for fracture treatment (Table
2). In vitro, most human BMPs were able to stimulate osteogenesis in mature osteoblasts, but BMP-6 and BMP-9 were more efficient in driving osteoblast differentiation of mesenchymal stem cells than BMP-2 and BMP-7 [
17]. BMP-6 and BMP-9 were also found to be more effective osteogenic factors in a mouse model for bone regeneration compared to BMP-2 and BMP-7 [
61]. Moreover, BMP-6, BMP-9 and BMP-4 showed more osteogenic potential than the approved rhBMPs in a rat model [
9]. Also in rat, an adenoviral vector carrying BMP-6 (AdBMP-6) produced more rapid tissue calcification and induced bone formation by both intramembranous and endochondral ossification compared to an adenoviral vector containing BMP-2 (AdBMP-2) or BMP-4 (AdBMP-4) [
62]. Although these model studies suggest an effect of BMP-4 and BMP-6 on fracture healing, the osteogenic activity of these BMPs has not yet adequately been investigated in humans (Table
1). Recently, BMP-6 displayed significantly more pronounced BMP reporter activation, osteoblast differentiation and stimulation of fracture healing than the most closely related family member BMP-7 [
19,
63]. The higher ultimate effect is not due to the stimulating potential of BMP-6, but due to differences in the noggin-mediated negative feedback loop induced by these BMPs. Upon siRNA-mediated knockdown of noggin, BMP-7 appeared to be as effective in inducing BMP reporter activation and osteoblast differentiation as BMP-6. BMP-6 stimulation not only resulted in lower induction of noggin expression compared to BMP-7, but BMP-6 was also found to be almost insensitive to noggin-mediated inhibition. A lysine at position 60 (Lys-60) was identified as a key residue conferring noggin resistance within the BMP-6 protein, and introducing a lysine residue at the position corresponding to BMP-6 Lys-60 in BMP-7 and BMP-2 made these mutants more resistant to inhibition by noggin. Interestingly, BMP-9 also contains a lysine residue at this position and is, like BMP-6, not inhibited by noggin [
18,
19]. BMP-9 also emerged as one of the most potent inducers of osteogenic differentiation [
9,
17,
36,
61,
64,
65]. BMP-9 was shown to promote chondrogenic lineage differentiation of human multipotent mesenchymal cells. BMP-9 was more potent to maintain the expression of chondrocyte-specific extracellular matrix molecules than BMP-2 [
66]. Combined injection in mice of BMP-9 and BMP-3, a known inhibitor of BMPs, resulted in the formation of bone, indicating that BMP-3 did not have the inhibiting effect which it has on other BMPs [
61]. The highly increased osteogenic activity observed with BMP-9 may be due to the fact that it is not affected by BMP antagonists such as noggin and BMP-3, essentially removing the negative feedback loop. Alternatively, it is possible to engineer BMP variants, such as variants of the currently used BMP-2 and BMP-7, with increased noggin resistance by substituting the amino acid residue corresponding to BMP-6 Lys-60 for a lysine residue. An alternative for the current treatment with BMP-2 or BMP-7 homodimers, the use of BMP-2/7 heterodimers could also be considered. These heterodimers display increased osteogenic potential and improved fusion compared with BMP homodimers [
67]. Interestingly, BMP-2/7 heterodimers were found to induce lower levels of noggin expression and to be almost insensitive to noggin inhibition [
68]. Recently, heterodimers of BMP-2/6 have been shown to bind more strongly to BMP receptors and are more osteogenic than BMP-2 [
69].
Table 2
Properties of several BMPs. The resistance to noggin is caused by a lysine residue at position 60 in the molecule. Also the ability to induce differentiation in pluripotent and preosteoblastic cells is described. The possible induction of mineralised matrix by the different BMPs is described. The potency of superior BMPs with reference to less potent BMPs is explained
Resistance to noggin | | | | |
Inducing differentiation in stem cells [ 17] | Notable increase in induction | Notable increase in induction | Detectable, but marginal induction | Notable increase in induction |
Inducing differentiation in preosteoblastic cells [ 17] | Marked increase in induction | Marked increase in induction | Increase of induction at later time point | Marked increase in induction |
Induction of mineralised matrix [ 17] | Readily detectable nodules | Readily detectable nodules | Sparse, but detectable nodules | Readily detectable nodules |
Specific BMP more potent than other BMPs | | More potent than BMP-2 [ 62] | | Higher induction of expression with specific molecules than BMP-2 [ 66] |
Finally, another approach to enhance BMP-induced bone formation might be a combination with TGF-β. TGF-β is generally considered to inhibit BMP signalling [
70,
71]. However, recently we demonstrated that the inhibitory effects of TGF-β on BMP-induced osteoblast differentiation depend on the timing and environmental conditions of the co-stimulation, and that under well-controlled conditions, transient co-application of TGF-β can actually promote BMP-induced differentiation towards the osteoblast lineage [
72]. Co-application of TGF-β1 with BMP-2 has been shown to accelerate bone formation, to increase total bone volume and to improve fracture healing in mice compared to application of BMP-2 alone [
73]. Since TGF-β seems to stimulate early BMP-induced osteoblast differentiation whereas it inhibits late osteoblast differentiation and mineralisation, it can be considered to initially combine BMP and TGF-β treatment followed by application of TGF-β antagonists to enhance the bone fracture healing process.